Chardan Capital Trims Immuneering (NASDAQ:IMRX) Target Price to $12.00

Immuneering (NASDAQ:IMRX) had its target price reduced by Chardan Capital from $16.00 to $12.00 in a research report report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock.

Separately, Needham & Company LLC reissued a buy rating and issued a $15.00 price target on shares of Immuneering in a report on Wednesday, May 8th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $12.60.

Immuneering Stock Down 2.7 %

Shares of Immuneering stock traded down $0.03 on Wednesday, reaching $1.09. 582,559 shares of the stock were exchanged, compared to its average volume of 944,756. Immuneering has a twelve month low of $1.05 and a twelve month high of $10.45. The firm has a market capitalization of $32.32 million, a price-to-earnings ratio of -0.58 and a beta of -0.61. The business has a 50 day moving average price of $1.30 and a two-hundred day moving average price of $2.79.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. Research analysts forecast that Immuneering will post -1.93 EPS for the current year.

Institutional Trading of Immuneering

Several large investors have recently made changes to their positions in the company. Acadian Asset Management LLC purchased a new stake in shares of Immuneering during the second quarter worth approximately $67,000. Vanguard Group Inc. grew its holdings in Immuneering by 12.1% in the 1st quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock valued at $3,479,000 after buying an additional 129,851 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Immuneering in the 2nd quarter valued at $447,000. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.